Tirzepatide
What is Tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. By mimicking both incretin hormones, it exerts a synergistic effect on glucose metabolism and satiety that surpasses selective GLP-1 agonists (like Semaglutide). GIP activation enhances insulin secretion and may improve lipid metabolism, while GLP-1 slows gastric emptying and signals satiety in the brain. Clinical trials have demonstrated superior weight loss and A1C reduction compared to other agents. It is FDA-approved for type 2 diabetes and chronic weight management. Tirzepatide represents a major advancement in metabolic therapy.
Benefits
- Significant Weight Loss (up to 20%+)
- Improved Blood Sugar Control
- Reduced Appetite & Cravings
- Cardiovascular Risk Reduction
- Improved Lipid Profile
- Metabolic Health Enhancement
Typical Dosage
- 2.5mg weekly (starting)
- 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly (titration steps)
Side Effects
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Abdominal pain
Dosage Protocol
Tirzepatide is administered once weekly via subcutaneous injection. The protocol requires strict titration to mitigate gastrointestinal side effects. Start at 2.5 mg weekly for 4 weeks. Increase to 5 mg weekly for at least 4 weeks. If needed and tolerated, increase in 2.5 mg increments every 4 weeks to target doses of 10 mg or 15 mg. Maximum dose is 15 mg weekly. Administer on the same day each week, with or without food.
Reconstitution
Dosing Schedule
Standard Protocol
- •Weeks 1-4: 2.5 mg once weekly
- •Weeks 5-8: 5 mg once weekly
- •Weeks 9-12: 7.5 mg once weekly (if needed)
- •Maintenance: 5mg, 10mg, or 15mg weekly based on response
Negative Interactions
- Insulin (hypoglycemia risk)
- Alcohol
- Other GLP-1 agonists
Tirzepatide is a potent prescription medication. Use under medical supervision. Risk of thyroid C-cell tumors (boxed warning).